Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.
Abstract
Systematic review and meta-analysis of observational studies was conducted in PubMed, Embase, and Web of Science from 2006 to 2025. 28 observational studies (6 for semaglutide and 22 for all GLP-1 RAs) involving T2DM patients were included. When compared to other antidiabetic treatments, GLP-1 RAs did not increase the risk of developing ocular disorders such as NAION (RR, 1.01; 95% CI, 0.62-1.64; I2, 89%), glaucoma (HR, 0.84; 95% CI, 0.71-1.00; I2, 91%), and retinopathy (HR, 0.96; 95% CI, 0.85-1.08). Even if no difference was observed, it is optimal to monitor the administration of these molecules.
Overview
CoChat Summary
## TL;DR
This systematic review and meta-analysis of 28 observational studies found no statistically significant increase in ocular adverse events with GLP-1 receptor agonists versus other antidiabetic drugs for NAION, glaucoma, or diabetic retinopathy. The authors still recommend monitoring, because the evidence showed high heterogeneity and some outcomes were driven by only a few studies.
## Key findings
- The review included 28 observational studies: 6 single-arm studies and 22 double-/three-arm studies, all in T2DM patients.
- In the overall analysis, GLP-1 RAs did not increase risk of NAION: RR 1.01 (95% CI 0.62–1.64; I² = 89%).
- GLP-1 RAs did not increase risk of glaucoma relative to non-GLP-1 comparators: HR 0.84 (95% CI 0.71–1.00; I² = 91%).
- GLP-1 RAs did not increase risk of new-onset diabetic retinopathy: HR 0.96 (95% CI 0.85–1.08; I² = 91%), and did not increase risk of retinopathy progression: HR 0.97 (95% CI 0.83–1.14; I² = 65%).
- In single-arm studies, the pooled prevalence of ocular adverse events was 2% (95% CI 0.01–0.03), and the pooled prevalence of diabetic retinopathy was 4% (95% CI 0.01–0.08).
## Methods
- Design: PRISMA-guided systematic review and random-effects meta-analysis of observational studies, registered in PROSPERO (CRD420251080120).
- Data/sample: Searches of PubMed, Embase, and Web of Science from 1 January 2006 to 7 March 2025 identified 5,713 articles; 28 observational studies met inclusion criteria. Included populations had T2DM and/or overweight/obesity and used GLP-1 RAs such as semaglutide, dulaglutide, liraglutide, lixisenatide, exenatide, or tirzepatide.
- Main analysis: Random-effects meta-analysis of ocular outcomes (NAION, glaucoma, new-onset DR, DR progression); heterogeneity was assessed with Q and I², publication bias with funnel plots when possible, and leave-one-out sensitivity analyses were performed.
## Limitations
- The paper explicitly states that the meta-analysis is limited by substantial heterogeneity, different study characteristics (sample size, geography, follow-up), limited subgroup data, and possible confounding from concomitant antidiabetic therapies.
- The paper also states that many studies lacked detailed clinical/biochemical data or disease severity information, and that some outcomes, especially NAION, were based on few studies, making estimates less robust.
- Evident from the text: because nearly all included studies were observational and many were retrospective, the results are vulnerable to confounding and selection bias.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
1 Valid · 0 Not valid · 2 Not checked · 20 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When compared to other antidiabetic treatments, GLP-1 RAs did not increase the risk of developing ocular disorders such as NAION (RR, 1.01; 95% CI, 0.62–1.64; I2, 89%)”
- Also stated in: § Double-arm studies comparing semaglutide vs. non-GLP-1 RAs · plain
“The results of the analysis stratified by the diabetic population did not show a statistically significant increased risk of developing NAION in the semaglutide group compared to that with other treatments (RR: 1.01; 95% CI: 0.62–1.64)”
- Also stated in: § Discussion · plain
“Literature data evaluated in our meta-analysis, most of which were related to semaglutide, did not show an increased risk of developing NAION in the semaglutide group compared to that in other GLP-1 RAs (RR: 1.01; IC 0.62–1.64).”
§ Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Double-arm studies comparing semaglutide vs. non-GLP-1 RAs · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“retinopathy (new onset or progression) [(HR, 0.96; 95% CI, 0.85–1.08; I2, 91%)”
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
“Combining the results from all these studies, no statistically significant differences between the groups were found in terms of new-onset of DR (HR: 0.96; 95% CI: 0.85–1.08), with very high heterogeneity among the studies (I2, 91%; p < 0.001)”
- Also stated in: § Discussion · plain
“our results showed a slightly not statistically significant increased risk of developing new-onset DR or DR in the non-GLP-1 group (HR, 0.96; 95% CI: 0.85–1.08”
§ Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“glaucoma (HR, 0.84; 95% CI, 0.71–1.00; I2, 91%)”
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
“The overall risk showed a statistically increased risk of developing glaucoma in the non-GLP-1 RAs group (HR: 0.84; 95% CI: 0.71–1.00) with high heterogeneity (I2, 91%; p < 0.001)”
- Also stated in: § Discussion · hedged
“In line with their results, an increased risk of developing glaucoma in the non-GLP-1 RAs group was detected (HR: 0.84; 95% CI: 0.71–1.00), even if it was not statistically significant”
§ Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“(HR, 0.97; 95% CI, 0.83–1.14; I2, 65%)”
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
“Overall, no statistically significant differences between the groups (HR: 0.97; 95% CI: 0.83–1.14) were found; heterogeneity among the studies was moderate (I2, 65%; p < 0.001)”
- Also stated in: § Discussion · hedged
“our results showed a slightly not statistically significant increased risk of developing new-onset DR or DR in the non-GLP-1 group (HR, 0.96; 95% CI: 0.85–1.08; HR, 0.97; 95% CI: 0.83–1.14).”
§ Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 28 observational studies (6 for semaglutide and 22 for all GLP-1 RAs) involving T2DM patients were included.”
- Also stated in: § Studies’ characteristics · plain
“A total of 5,713 articles were identified from the three databases (Figure 1). After the removal of duplicates (n = 2,176) and following full-text screening, 28 observational studies met the inclusion criteria and were included in the review”
§ Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Studies’ characteristics · plain
6 more claims
Create a free account to see all 23 claims and every source verdict.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 5
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“…risk of developing DR in some clinical studies, such as the SUSTAIN 6 cardiovascular outcome trial, which compared semaglutide to placebo (HR, 1.76; 95% CI, 1.11–2.78) (Marso et al., 2016a) and the LEADER cardiovascular outcome trial which compared liraglutide to placebo (Marso et al., 2016b).”
InfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“…risk of developing DR in some clinical studies, such as the SUSTAIN 6 cardiovascular outcome trial, which compared semaglutide to placebo (HR, 1.76; 95% CI, 1.11–2.78) (Marso et al., 2016a) and the LEADER cardiovascular outcome trial which compared liraglutide to placebo (Marso et al., 2016b).”
InfluentialThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003583 · Cited by 5,148
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779 · cited 1×
“…further sensitivity analyses; however, the limited number of studies and data presented for each outcome advisable, considering, for example, the duration of diabetes, the treatment duration with GLP-1 Ras, and the influence of previously concomitantly received medications (Sterne and Egger, 2001).”
Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments
Lo, C. K.-L., Mertz, D., & Loeb, M. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-45 · Cited by 2,477 · cited 3×
“Regarding the study design, 27 of them were cohort studies [three prospective (Grauslund et al., 2026; Lo et al., 2014; Caballero Mateo et al., 2024), 23 retrospective (Chou et al., 2024; Simonsen et al., 2024; Albargawi et al., 2024; Mahzari et al., 2024; Mayer and Fontelo, 2024; Douros et al.,…”
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“…in blood glucose levels and glycated hemoglobin, increase in insulin secretion in hyperglycemic conditions, inhibition of glucagon release, protection of β -cell function, improvement of cardio-renal function, and inhibition of gastric emptying (Movahednasab et al., 2025; Nauck et al., 2021).”
Diabetic Retinopathy: Pathophysiology and Treatments
Wang, W., & Lo, A. C. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061816 · Cited by 1,358 · cited 1×
“Inflammation is involved in the pathophysiology of DR as well (Wang and Lo, 2018).”
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · cited 1×
“Injection-site reactions, headache, and nasopharyngitis are other common non-serious and reversible AEs (Wojtara et al., 2023; An et al., 2025; Filippatos et al., 2014; Davies et al., 2022).”
Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy
Lin, K., Hsih, W., Lin, Y., Wen, C., & Chang, T. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13480 · Cited by 446 · cited 1×
“If PDR is not treated, it can turn into visual impairment with retinal detachment (Zheng et al., 2023; Hui et al., 2024; Lin et al., 2021).”
Research works printed but not linked: 5
- PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines ozempic, Rybelsus Wegovy
- Summary of Product Characteristics (Saxenda)
- Summary of Product Characteristics (Wegovy)
- Summary of Product Characteristics (Mounjaro)
- International Diabetes Federation. IDF Diabetes Atlas, 2021, IDF Diabetes Atlas
Cited by
Alabed, S. T., Thomas, A., Szirth, B. C., & Khouri, A. S. (2026) · Neuro-Ophthalmology · doi:10.1080/01658107.2026.2741570
Metadata
- Authors
- Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Corresponding author
- Liguori, Valerio
- Venue
- Frontiers in pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2026-06-02
- Volume
- 17
- Pages
- 1808359-1808359
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC13269103
- OpenAlex
- W7163212561
- Cited by
- 3
- References
- 73
- Citations by year
- 2026: 3
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- GLP-1 receptor agonists, ocular adverse effects, retinopathy, glaucoma, nonarteritic anterior ischemic optic neuropathy, semaglutide, type 2 diabetes, drug safety, antidiabetic drugs, obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies. https://app.cochat.ai/papers/10.3389/fphar.2026.1808359
- The paper
- Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026). Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1808359
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.